Home › Trial NCT05826535
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Trial IDNCT05826535
- StatusRecruiting
- PhasePhase 1/2
- Study typeInterventional
- SponsorLyell Immunopharma, Inc.
- Enrollment270
- Start date2023-05-09
- ConditionsRelapsed Non-Hodgkin Lymphoma · Refractory Non-Hodgkin Lymphoma · Non-Hodgkin Lymphoma · Large B-cell Lymphoma
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.